BioStock: Progress for SynAct Pharma in 2022 – more milestones ahead

SynAct Pharma recently published the year-end report for 2022, presenting great progress in its pipeline with the lead compound AP1189. Now they have another exciting and crucial year ahead of them with several data read-outs from the three clinical trials with AP1189. Following the acquisition of TXP Pharma, they also have a substantially expanded portfolio of melanocortin peptides to explore.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/02/progress-for-synact-pharma-in-2022-more-milestones-ahead/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se